Literature DB >> 11286471

Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.

Y Suefuji1, T Sasatomi, S Shichijo, S Nakagawa, H Deguchi, T Koga, T Kameyama, K Itoh.   

Abstract

We recently reported the SART3 tumour-rejection antigen as possessing tumour epitopes capable of inducing HLA-class I-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in breast cancer to explore an appropriate molecule for use in specific immunotherapy of breast cancer patients. The SART3 antigen was detected in all of the breast cancer cell lines tested, 30 of 40 (75%) breast cancer tissue samples, and 0 of 3 non-tumourous breast tissue samples. SART3 derived peptides at positions 109-118 and 315-323 induced HLA-A24 restricted CTLs that reacted to breast cancer cells from the peripheral blood mononuclear cells (PBMCs) of breast cancer patients. Therefore, the SART3 antigen and its peptides could be an appropriate molecule for use in specific immunotherapy of the majority of HLA-A24-positive breast cancer patients. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11286471      PMCID： PMC2363830          DOI： 10.1054/bjoc.2000.1690

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  22 in total

1.  The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.

Authors:  P F Robbins; M El-Gamil; Y F Li; E B Fitzgerald; Y Kawakami; S A Rosenberg
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

2.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

3.  Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

Authors:  H Yamauchi; A O'Neill; R Gelman; W Carney; D Y Tenney; S Hösch; D F Hayes
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

4.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors:  F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

5.  A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

Authors:  P van der Bruggen; J Bastin; T Gajewski; P G Coulie; P Boël; C De Smet; C Traversari; A Townsend; T Boon
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

6.  Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

Authors:  D C Linehan; P S Goedegebuure; G E Peoples; S O Rogers; T J Eberlein
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

7.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

Authors:  Y Kawakami; S Eliyahu; C Jennings; K Sakaguchi; X Kang; S Southwood; P F Robbins; A Sette; E Appella; S A Rosenberg
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

8.  Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo.

Authors:  F Farace; E Angevin; P Y Dietrich; C Leboullaire; J Vanderplancke; B Escudier; F Triebel
Journal:  Int J Cancer       Date:  1995-09-04       Impact factor: 7.396

9.  IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer.

Authors:  C Traversari; R Meazza; M Coppolecchia; S Basso; A Verrecchia; P van der Bruggen; A Ardizzoni; A Gaggero; S Ferrini
Journal:  Gene Ther       Date:  1997-10       Impact factor: 5.250

10.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Authors:  P F Robbins; M El-Gamil; Y F Li; Y Kawakami; D Loftus; E Appella; S A Rosenberg
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307
View more
  9 in total

1.  The RNA-binding protein SART3 promotes miR-34a biogenesis and G1 cell cycle arrest in lung cancer cells.

Authors:  Emily J Sherman; Dylan C Mitchell; Amanda L Garner
Journal:  J Biol Chem       Date:  2019-10-16       Impact factor: 5.157

2.  Tip110 Regulates the Cross Talk between p53 and Hypoxia-Inducible Factor 1α under Hypoxia and Promotes Survival of Cancer Cells.

Authors:  Khalid Amine Timani; Ying Liu; Yan Fan; Khalid S Mohammad; Johnny J He
Journal:  Mol Cell Biol       Date:  2015-05-04       Impact factor: 4.272

3.  p110, a novel human U6 snRNP protein and U4/U6 snRNP recycling factor.

Authors:  Mathias Bell; Silke Schreiner; Andrey Damianov; Ram Reddy; Albrecht Bindereif
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

4.  Structural Basis of the Recruitment of Ubiquitin-specific Protease USP15 by Spliceosome Recycling Factor SART3.

Authors:  Qi Zhang; Rachel Harding; Feng Hou; Aiping Dong; John R Walker; Joseph Bteich; Yufeng Tong
Journal:  J Biol Chem       Date:  2016-06-02       Impact factor: 5.157

5.  Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.

Authors:  Philipp Erben; Darko Gosenca; Martin C Müller; Jelena Reinhard; Joannah Score; Francesco Del Valle; Christoph Walz; Jürgen Mix; Georgia Metzgeroth; Thomas Ernst; Claudia Haferlach; Nicholas C P Cross; Andreas Hochhaus; Andreas Reiter
Journal:  Haematologica       Date:  2010-01-27       Impact factor: 9.941

6.  Tip110 interacts with YB-1 and regulates each other's function.

Authors:  Khalid Amine Timani; Ying Liu; Johnny J He
Journal:  BMC Mol Biol       Date:  2013-07-04       Impact factor: 2.946

7.  Oxygen atoms are critical in rendering THP-1 leukaemia cells susceptible to cold physical plasma-induced apoptosis.

Authors:  Sander Bekeschus; Kristian Wende; Mohamed Mokhtar Hefny; Katrin Rödder; Helena Jablonowski; Anke Schmidt; Thomas von Woedtke; Klaus-Dieter Weltmann; Jan Benedikt
Journal:  Sci Rep       Date:  2017-06-05       Impact factor: 4.379

8.  Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion.

Authors:  Alejandro Athie; Francesco P Marchese; Jovanna González; Teresa Lozano; Ivan Raimondi; Prasanna Kumar Juvvuna; Amaya Abad; Oskar Marin-Bejar; Jacques Serizay; Dannys Martínez; Daniel Ajona; Maria Jose Pajares; Juan Sandoval; Luis M Montuenga; Chandrasekhar Kanduri; Juan J Lasarte; Maite Huarte
Journal:  J Cell Biol       Date:  2020-09-07       Impact factor: 10.539

9.  Effects of Combinatorial Ubiquitinated Protein-Based Nanovaccine and STING Agonist in Mice With Drug-Resistant and Metastatic Breast Cancer.

Authors:  Fang Huang; Ning Pan; Yiting Wei; Jinjin Zhao; Mohanad Aldarouish; Xuru Wang; Xiaotong Sun; Zhifa Wen; Yongqiang Chen; Lixin Wang
Journal:  Front Immunol       Date:  2021-09-13       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.